about
OfatumumabRecombinant antibodies: a novel approach to cancer diagnosis and therapy.Overview of mimotopes and related strategies in tumor vaccine development.Phylogenetic analysis of the MS4A and TMEM176 gene familiesAntibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.CD20-mediated apoptosis: signalling through lipid rafts.Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.Prospects for B-cell-targeted therapy in autoimmune disease.Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.B cells in autoimmunity.The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.Rituximab: applications in dermatology.Improving the efficacy of trastuzumab in breast cancer.Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trialPost-transplant lymphoproliferative disorders following solid-organ transplantation.Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.An open study of B lymphocyte depletion in systemic lupus erythematosus.Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.In vivo tumouricidal effects of LAD-1 monoclonal antibody on murine RL-male-1 lymphoma mediated by enhanced phagocytosis.Primary small-bowel non-Hodgkin's lymphoma: a study of clinical features, pathology, management and prognosis.
P2860
Q24651912-B68B0B05-28F8-4CEB-A3FB-E056CEFAA048Q33181384-3F1AF3FE-2C2A-4935-B0AF-409F636CB1D5Q33389252-EEAB3377-76AB-486C-AF2B-EE760EB8318BQ33534692-576B9768-F538-4BA0-A2DA-4B93415E29D1Q34452700-2ABD5051-60E2-42C5-AB55-41D912602ABBQ34969960-07FC11AC-9026-4D27-ABED-65BAFAAA8802Q35551028-2EA95DE9-9967-44E6-94B2-C5CD4847E6C9Q35930307-868D08FF-34C1-4570-B9B4-B007DB6DFDA4Q36066311-56DCD6FA-DBD9-444F-A339-77B388995DDBQ36104953-FE0F4470-9B0D-4C4A-B24E-55DF292DB853Q36561648-66665686-A81F-44C0-A3C7-29416A1D1F27Q36623217-85656F8D-8341-4219-AD55-8DA790D2F232Q36788591-9AF49390-195B-4A01-89F3-0D115E8C211EQ37144563-1B20F273-3309-4A94-B877-8E7FBE89E57DQ37810068-DC063728-DA47-4250-A274-969A0DE19CB9Q42165272-E0B94DC5-1053-4D61-A152-2A441FAE0723Q44183280-AAADC80B-0C95-458F-9F66-2D61A4FBB318Q45855065-60E9B077-6A76-40DF-B062-0F705CD14D66Q46548617-A7B1F106-7A3C-437B-AF68-55F1025A583EQ51748843-7AFA31AD-5D56-4BBE-9A29-5D4CC7A7D361
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Clinical applications of anti-CD20 antibodies.
@ast
Clinical applications of anti-CD20 antibodies.
@en
type
label
Clinical applications of anti-CD20 antibodies.
@ast
Clinical applications of anti-CD20 antibodies.
@en
prefLabel
Clinical applications of anti-CD20 antibodies.
@ast
Clinical applications of anti-CD20 antibodies.
@en
P1476
Clinical applications of anti-CD20 antibodies
@en
P2093
P304
P356
10.1016/S0022-2143(99)90164-6
P577
1999-11-01T00:00:00Z